New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)
Summary
(RHHBY) Basel, 05 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data from the AVONELLE-X and SALWEEN studies of Vabysmo® (faricimab),1,2 presented at the 25th Euretina Congress in Paris, France. Data from the open-label AVONELLE-X study reinforce the efficacy, safety and durability of Vabysmo over four years in neovascular or “wet” age-related macular degeneration (nAMD), a leading cause of vision loss.1 In the single-arm SALWEEN study, Vabysmo showed clinically meaningful vision gains and retinal drying over one year in polypoidal choroidal vasculopathy (PCV), a vision-threatening subtype of nAMD that is especially common in Asia.2
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 5, 2025 by globenewswire